Professor Claude M. Wischik, co-founder and Executive Chairman of TauRx Therapeutics, along with colleagues at the University of Aberdeen, has devoted nearly 30 years to investigating the structure and role of tau tangles in the development of Alzheimer’s, frontotemporal dementia and other neurodegenerative diseases. Prof. Wischik discovered that the neurofibrillary tangles seen in Alzheimer’s disease are made of sub-units of the tau protein and he and his team have published extensively in the field.

Lutter, L., et al (2022) Structural Identification of Individual Helical Amyloid Filaments by Integration
of Cryo-Electron Microscopy-Derived Maps in Comparative Morphometric Atomic Force Microscopy Image Analysis. Available at Journal of Molecular Biology

Santos. R.X., et al (2022) HMTM-Mediated Enhancement of Brain Bioenergetics in a
Mouse Tauopathy Model Is Blocked by Chronic Administration
of Rivastigmine. Available at Biomedicines

Schwab, K., et al (2022) Glutamatergic transmission and receptor expression in the synucleinopathy h-α-synL62 mouse model: Effects of hydromethylthionine. Available at Cellular Signalling

Wischik, C.M., et al (2022) Oral Tau Aggregation Inhibitor for Alzheimer’s Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate. Available at The Journal of Prevention of Alzheimer's Disease